These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36503381)

  • 1. Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019.
    Gao Q; Yin X; Tan B; Wang J; Chen J; Zhao B; Yang Q; Li Z
    BMC Infect Dis; 2022 Dec; 22(1):929. PubMed ID: 36503381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.
    Muhović D; Bojović J; Bulatović A; Vukčević B; Ratković M; Lazović R; Smolović B
    Liver Int; 2020 Aug; 40(8):1901-1905. PubMed ID: 32478465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.
    Wei C; Liu Y; Jiang A; Wu B
    Int J Clin Pharm; 2022 Jun; 44(3):709-716. PubMed ID: 35364753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.
    Swets MC; Moss RJ; Kor F; Hilarius D; Moes DJAR; Berkhout WE; van den Toorn LM; van den Oever NCG; de Valk R; Rosendaal FR; Hunfeld N; Groeneveld GH; de Boer MGJ
    Int J Infect Dis; 2023 Apr; 129():57-62. PubMed ID: 36738957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Early use of tocilizumab in hospitalized patients with severe and critical COVID-19 in the Province of Buenos Aires: a multicentric study].
    Salazar M; Varela Baino AN; González S; González Martínez V; Varela T; Regairaz L; Torres K; Kreplak N; Estenssoro E
    Medicina (B Aires); 2023; 83(2):190-201. PubMed ID: 37094187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
    Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
    Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis.
    Zeraatkar D; Cusano E; Martínez JPD; Qasim A; Mangala S; Kum E; Bartoszko JJ; Devji T; Agoritsas T; Guyatt G; Izcovich A; Khamis AM; Lamontagne F; Rochwerg B; Vandvik P; Brignardello-Petersen R; Siemieniuk RAC
    BMJ Med; 2022; 1(1):e000036. PubMed ID: 36936570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and tocilizumab in rheumatoid arthritis patients.
    Saito S; Suzuki K; Yoshimoto K; Kondo Y; Kikuchi J; Hanaoka H; Kaneko Y; Takeuchi T
    Clin Exp Rheumatol; 2023 Jul; 41(7):1451-1455. PubMed ID: 36533996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
    Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
    Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
    Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
    JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
    Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
    J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.
    Rubio-Rivas M; Ronda M; Padulles A; Mitjavila F; Riera-Mestre A; García-Forero C; Iriarte A; Mora JM; Padulles N; Gonzalez M; Solanich X; Gasa M; Suarez-Cuartin G; Sabater J; Perez-Fernandez XL; Santacana E; Leiva E; Ariza-Sole A; Dallaglio PD; Quero M; Soriano A; Pasqualetto A; Koo M; Esteve V; Antoli A; Moreno-Gonzalez R; Yun S; Cerda P; Llaberia M; Formiga F; Fanlo M; Montero A; Chivite D; Capdevila O; Bolao F; Pinto X; Llop J; Sabate A; Guardiola J; Cruzado JM; Comin-Colet J; Santos S; Jodar R; Corbella X
    Int J Infect Dis; 2020 Dec; 101():290-297. PubMed ID: 33035673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System.
    Flaig T; Douros A; Bronder E; Klimpel A; Kreutz R; Garbe E
    J Clin Pharm Ther; 2016 Dec; 41(6):718-721. PubMed ID: 27670839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study.
    Ibrahem HY; Aly DH; Warda AEA; Farahat RA; Youssef RM; Abdelhamid MH; Goud HA; Mohamed RR; Eldien MAYN; Alotaibi FO; Alzarea AI; Alanazi AS; Eisa NM; Refaee AS
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676678
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury
    Rana P; Aleo MD; Wen X; Kogut S
    Acta Pharm Sin B; 2021 Dec; 11(12):3857-3868. PubMed ID: 35024312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.